drugset / Trial / NCT04040231
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
Timeline
- Start
- 2019-07-24
- Primary completion
- 2024-11-14
- Completion
- 2024-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galinpepimut-S | Vaccine | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Background | sargramostim | Protein / enzyme biologic | 70 ug | Subcutaneous |